Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire 10 days ago

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire 10 days ago

Medicenna shares preclinical data on treatment targeting tumours

Jocelyn Aspa 10 days ago

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewswire 10 days ago

Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 4, 2024

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

GlobeNewswire March 6, 2024

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

GlobeNewswire February 14, 2024

Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

GlobeNewswire February 13, 2024

Medicenna Announces Appointment of New Auditor

GlobeNewswire January 12, 2024

Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

GlobeNewswire January 9, 2024

Medicenna Extends Period to Exercise Certain Warrants

GlobeNewswire December 21, 2023

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

GlobeNewswire December 19, 2023

Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology

GlobeNewswire November 17, 2023

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

GlobeNewswire November 14, 2023

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

GlobeNewswire November 9, 2023

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 6, 2023

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 3, 2023

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

GlobeNewswire October 27, 2023

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

GlobeNewswire October 25, 2023

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

GlobeNewswire October 24, 2023